EVMN ▼ -25.2% - Evommune, Inc. $EVMN - Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis Evommune shares fell 25.2% following the company's announcement of top-line results from its Phase 2b trial of EVO756 in moderate-to-severe atopic dermatitis. The significant selloff suggests the trial results disappointed investors relative to prior expectations for the experimental treatment. 08-SEP-2026 05:48 PM ET